Certican derives Successful Result

.

Certican derives Successful Result

Surely, it was a good news for Novartis that it has been able to have positive result of its phase III clinical study of immune system drug known as Certican. The news was worth getting happy, as it has been found that the Swiss pharmaceutical company was trying to get everything right for last two years.

In addition, it has been said that the project is considered to be the biggest project that has been taken out by the company with regard to liver transplant. It has been found that the drug is quite effective in improving renal function among patients.

The data about the same was revealed at the meeting of American Association for the Study of Liver Diseases (AASLD), which is in its 63rd year. The drug, which has already received approval from European health authorities, is likely to get approval from the US health regulators Food and Drug Administration by the end of 2012.

"These results showed that treatment with Certican with reduced tacrolimus led to a clinically relevant retention of renal function compared to standard tacrolimus, with no compromise in rejection", said John Fung, who is positioned as director at Transplantation Center. It is expected that the drug is able to provide benefit to adults suffering from liver problem.


Latest News

Kidney deaths at hospitals can be avoided
Movement makes some people feel sick
ADHD kids suffer language problems
‘Fit mother’ brand is not easy today
Apple releases new video to highlight its focus on environment and resource cons
Yale University professor claims Apple patents worth only $38 million, not billi
AT&T plans to expand its fiber optics service
Nokia, Microsoft deal likely to be finalized by April 25
Netflix opposes Comcast-TWC merger
Airbnb permanently removing over 2,000 New York listings which could be illegal
FDA Proposal Could Result in Increased Prices of Beer
Patients spend more for free drug samples from doctors